THE NEWS: Roche Holding AG reported a 6 percent increase in sales for the first nine months of the year, helped by strong demand for its established and new cancer drugs.
THE NUMBERS: The Swiss drugmaker said sales rose to 34.9 billion Swiss francs ($38.2 billion) from 33.7 billion francs in the same time period last year. For the quarter ended in September, sales rose 8 percent to 11.6 billion francs.
THE OUTLOOK: Roche said the outlook for its breast cancer medicines improved in September after the European regulatory agency recommended approval for Kadcyla in advanced cases and U.S. regulators granted accelerated approval of Perjeta for treatment before surgery.
- Investment & Company Information
- Roche Holding AG